This should be further explored due to the emerging interest in 5-HT2A agonists for treating anxiety and depression, such as the LSD-like psychedelic drugs that acting as 5-HT2A agonists display rapid antidepressant effects related to their neuroplastic actions (Corne and Mongeau, 2019; Carhart-Harris et al., 2021; Tariq, 2022). Here, HTR2A is linked to depressive disorder.